NASDAQ:HLVX HilleVax Q4 2023 Earnings Report $1.84 -0.02 (-0.81%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$1.88 +0.03 (+1.63%) As of 05/30/2025 04:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast HilleVax EPS ResultsActual EPS-$0.78Consensus EPS -$0.80Beat/MissBeat by +$0.02One Year Ago EPSN/AHilleVax Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AHilleVax Announcement DetailsQuarterQ4 2023Date3/20/2024TimeN/AConference Call DateWednesday, March 20, 2024Conference Call Time8:00AM ETUpcoming EarningsHilleVax's Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Friday, August 8, 2025 at 6:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) HilleVax Earnings HeadlinesBrokerages Set HilleVax, Inc. (NASDAQ:HLVX) PT at $3.00May 23, 2025 | americanbankingnews.comHilleVax, Inc. (NASDAQ:HLVX) is largely controlled by institutional shareholders who own 51% of the companyMay 22, 2025 | finance.yahoo.comBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle of the Utah's Black Desert. Why? Not for oil discovery. Or uranium or solar. Instead, what’s happening beneath this patch of sand is the discovery of a new kind of energy. Google, Buffett, and a even tech billionaires like Gates, Bezos, and Zuckerberg are grabbing a stake.June 1, 2025 | Stansberry Research (Ad)HilleVax, Inc.: HilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 9, 2025 | finanznachrichten.deHilleVax Reports First Quarter 2025 Financial Results and Highlights Recent Company ProgressMay 8, 2025 | globenewswire.comHilleVax Reports Full Year 2024 Financial Results and Highlights Recent Company ProgressMarch 28, 2025 | globenewswire.comSee More HilleVax Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like HilleVax? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HilleVax and other key companies, straight to your email. Email Address About HilleVaxHilleVax (NASDAQ:HLVX), a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.View HilleVax ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles e.l.f. Beauty Sees Record Surge After Earnings, Rhode DealCrowdStrike Stock Slips: Analyst Downgrades Before Earnings Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsAdvance Auto Parts: Did Earnings Defuse Tariff Concerns?Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH StockAdvance Auto Parts Jumps on Surprise Earnings BeatAlibaba's Earnings Just Changed Everything for the Stock Upcoming Earnings CrowdStrike (6/3/2025)Haleon (6/4/2025)Broadcom (6/5/2025)Oracle (6/10/2025)Adobe (6/12/2025)Accenture (6/20/2025)FedEx (6/24/2025)Micron Technology (6/25/2025)Paychex (6/25/2025)NIKE (6/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
